Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CTSC | P53634 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 13/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806244 | 0.94 | CTSL (0.54) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3808657 | 0.90 | CTSL (0.49) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3808431 | 0.90 | CTSL (0.49) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3811443 | 0.90 | CTSL (0.53) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3808413 | 0.90 | CTSL (0.48) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3815030 | 0.89 | TSHR (0.44) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3808370 | 0.89 | CTSL (0.49) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3816034 | 0.87 | CTSL (0.49) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3815925 | 0.86 | CTSL (0.48) | CTSLCTSSCTSKCTSBL3MBTL1 | |
| SCHEMBL3814199 | 0.86 | CTSL (0.48) | CTSLCTSSCTSKCTSBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264498-A1 | Cathepsin C Inhibitors | CTSF, CTSZ, CTSG | CTSL 9/4885CTSS 5/4885CTSK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.